FDA expands use of Kisqali
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
US FDA declines to approve Vanda's stomach condition drug
Vanda Pharmaceuticals said on Thursday the U.S. Food and Drug Administration declined to approve its drug to treat a type of stomach condition that disrupts digestion and called for additional studies.
FDA Expands Use of Breast Cancer Drug Kisqali
The FDA approval of Kisqali for this early breast cancer population, including those with NO [hasn't spread to nearby lymph nodes] disease, is a pivotal moment in improving our approach to care,” said Dr.
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The approval means that tens of thousands of women diagnosed with early-stage breast cancer will have access to a medication that can help prevent their cancer from coming back. “Depending on your risks and everything,
FDA approves Novartis Kisqali(R) to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 -- Kisqali(R) (ribociclib) significantly reduced the risk of recurrence by 25% vs.
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
FDA expanded their approval on drug cancer drug
First News
Merck wins 1st FDA approval for Keytruda
FDA finds some 'dairy-free' chocolate products contain milk
Consumers should be aware that some chocolate labeled as "dairy-free" actually contains milk, the U.S. Food and Drug ...
FDA approves Apple Watch sleep apnea detection tool
The function is not a diagnostic tool, but can tell watch-wearers if they are exhibiting signs of sleep apnea.
FiercePharma2h
Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection
From truckloads of torn documents to avian incursions in the production plant, Granules India’s recent manufacturing ...
Waffle Recall Update As FDA Sets Risk Level for 13 States
The products were voluntarily recalled "due to the potential presence of soft plastic film," leading them to be given a Class ...
The FDA wants to place warning labels on food packages to combat obesity and other health conditions
The Food and Drug Administration (FDA) is looking to propose the inclusion of front-of-package warning labels that detail the ...
First FDA Study of Kratom’s Effects Doesn’t Help Much
Greetings from Michelle in DC. After years of worry, US regulators are finally generating some early — very early — insights ...
Wegmans Nuts Recall Update As FDA Sets Risk Level For 8 States
Flagstone Foods LLC issued the recall in August for Wegmans' Food You Feel Good About Pecan Blend due to undeclared almonds.
FDA rejects Vanda Pharmaceuticals' application to bring key drug to market
A D.C. drugmaker has been dealt a major setback in its long-running bid to bring its treatment for a chronic gastrointestinal ...
FDA to investigate metals found in tampons after study; study's co-author 'excited' over probe
The FDA will now investigate metals found in tampons following the results of a recent study. The study's co-author weighs in ...
New York Post on MSN21h
‘Joe Rogan’ guest who ripped FDA sees mail-order pharmacy ReviveRX caught up in embarrassing recall
Houston-based ReviveRX — whose outspoken co-founder Brigham Buhler has been a regular on Rogan’s podcasts, opining on “FDA ...